MIDAGE-M1

Medicine Information

Product information:

MIDAGE-M1 Tablet is a fixed-dose combination of Glimepiride and Metformin Hydrochloride, two oral antidiabetic medicines with complementary mechanisms of action. Together, they help improve blood glucose control in adults with Type 2 diabetes mellitus when used along with appropriate diet and exercise.

Glimepiride stimulates the pancreas to release insulin, while Metformin helps reduce glucose production by the liver and improves the body's response to insulin.

Key Benefits:

Glimepiride stimulates pancreatic β‑cells to release insulin, while Metformin reduces hepatic glucose output and improves insulin sensitivity.
Combination therapy balances both fasting and post‑meal blood sugar levels.
Sustained glycemic control reduces long‑term diabetes complications.
Addresses both insulin deficiency and insulin resistance in type 2 diabetes.
Widely prescribed when monotherapy is insufficient for glycemic control.
Metformin minimizes weight gain risk, while Glimepiride ensures strong postprandial control.

Directions for use:

Take MIDAGE-M1 exactly as prescribed by your doctor. Take the tablet with food, preferably with the first main meal, as directed by your healthcare professional. Glimepiride is generally administered with breakfast or the first main meal of the day.

Swallow the tablet with water; do not crush or chew unless specifically advised. Follow the recommended diet and exercise plan advised by your doctor.

Storage and Safety Information:

Store in a cool, dry place away from direct sunlight and moisture.
Keep the medicine in its original packaging and out of reach of children.
Glimepiride may cause low blood sugar (hypoglycemia), particularly if meals are skipped, excessive alcohol is consumed, or the medicine is used in combination with other glucose-lowering medicines.
Do not skip meals after taking the medicine unless advised by your healthcare professional.
Inform your doctor if you have kidney or liver problems before starting treatment. Patients with renal impairment may require careful dose selection and monitoring.
Contact your doctor if you experience persistent dizziness, sweating, shaking, unusual weakness, confusion, or other symptoms suggestive of low blood sugar.
MIDAGE-M1 is not intended for the treatment of Type 1 diabetes mellitus or diabetic ketoacidosis.
For use under medical supervision.

Medicine Information

Product information:

Key Benefits:

Directions for use:

Storage and Safety Information:

Partner with us